Excess beta 2 microglobulin promoting functional peptide association with purified soluble class I MHC molecules. 1991

S Kozlowski, and T Takeshita, and W H Boehncke, and H Takahashi, and L F Boyd, and R N Germain, and J A Berzofsky, and D H Margulies
Molecular Biology Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892.

T lymphocytes expressing alpha beta receptors recognize antigenic peptide fragments bound to major histocompatibility complex class I or class II molecules present on the surface membranes of other cells. Peptide fragments are present in the two available HLA crystal structures and recent data indicate that peptide is required for the stable folding of the class I heavy chain and maintenance of its association with the class I light chain, beta 2-microglobulin (beta 2m), at physiological temperature. To explain how the exogenous peptide used to create targets for cytotoxic cells bearing CD8 antigen could associate with apparently peptide-filled extracellular class I molecules, we hypothesized that stable binding of exogenous peptide to mature class I molecules reflects either the replacement of previously bound peptide during the well documented beta 2m exchange process or the loading of 'empty' class I heavy chains dependent on the availability of excess beta 2m. In either case, free beta 2m should enhance peptide/class I binding. Using either isolated soluble class I molecules or living cells, we show here that free purified beta 2m markedly augments the generation of antigenic complexes capable of T-cell stimulation.

UI MeSH Term Description Entries
D011498 Protein Precursors Precursors, Protein
D002474 Cell-Free System A fractionated cell extract that maintains a biological function. A subcellular fraction isolated by ultracentrifugation or other separation techniques must first be isolated so that a process can be studied free from all of the complex side reactions that occur in a cell. The cell-free system is therefore widely used in cell biology. (From Alberts et al., Molecular Biology of the Cell, 2d ed, p166) Cellfree System,Cell Free System,Cell-Free Systems,Cellfree Systems,System, Cell-Free,System, Cellfree,Systems, Cell-Free,Systems, Cellfree
D006680 HLA Antigens Antigens determined by leukocyte loci found on chromosome 6, the major histocompatibility loci in humans. They are polypeptides or glycoproteins found on most nucleated cells and platelets, determine tissue types for transplantation, and are associated with certain diseases. Human Leukocyte Antigen,Human Leukocyte Antigens,Leukocyte Antigens,HL-A Antigens,Antigen, Human Leukocyte,Antigens, HL-A,Antigens, HLA,Antigens, Human Leukocyte,Antigens, Leukocyte,HL A Antigens,Leukocyte Antigen, Human,Leukocyte Antigens, Human
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006825 Hybridomas Cells artificially created by fusion of activated lymphocytes with neoplastic cells. The resulting hybrid cells are cloned and produce pure MONOCLONAL ANTIBODIES or T-cell products, identical to those produced by the immunologically competent parent cell. Hybridoma
D001613 beta 2-Microglobulin An 11-kDa protein associated with the outer membrane of many cells including LYMPHOCYTES. It is the small subunit of MHC CLASS I MOLECULES. Association with beta 2-microglobulin is generally required for the transport of class I heavy chains from the endoplasmic reticulum to the cell surface. Beta 2-microglobulin is present in small amounts in serum, CEREBROSPINAL FLUID, and urine of healthy individuals, and to a much greater degree in the urine and plasma of patients with tubular PROTEINURIA, renal failure, or kidney transplants. Thymotaxin,beta 2 Microglobulin
D013601 T-Lymphocytes Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen. T Cell,T Lymphocyte,T-Cells,Thymus-Dependent Lymphocytes,Cell, T,Cells, T,Lymphocyte, T,Lymphocyte, Thymus-Dependent,Lymphocytes, T,Lymphocytes, Thymus-Dependent,T Cells,T Lymphocytes,T-Cell,T-Lymphocyte,Thymus Dependent Lymphocytes,Thymus-Dependent Lymphocyte
D015686 Gene Products, env Retroviral proteins, often glycosylated, coded by the envelope (env) gene. They are usually synthesized as protein precursors (POLYPROTEINS) and later cleaved into the final viral envelope glycoproteins by a viral protease. env Gene Products,env Polyproteins,env Protein,env Antigens,env Glycoproteins,env Polyprotein,Antigens, env,Polyprotein, env,Polyproteins, env
D019302 HIV Envelope Protein gp160 An envelope protein of the human immunodeficiency virus that is encoded by the HIV env gene. It has a molecular weight of 160,000 kDa and contains numerous glycosylation sites. It serves as a precursor for both the HIV ENVELOPE PROTEIN GP120 and the HIV ENVELOPE PROTEIN GP41. Envelope Glycoprotein gp160, HIV,HTLV-III gp160,env Protein gp160, HIV,gp160(HIV),HIV Envelope Glycoprotein gp160,gp160 Envelope Glycoprotein, HIV,HTLV III gp160,gp160, HTLV-III

Related Publications

S Kozlowski, and T Takeshita, and W H Boehncke, and H Takahashi, and L F Boyd, and R N Germain, and J A Berzofsky, and D H Margulies
March 1991, Journal of immunology (Baltimore, Md. : 1950),
S Kozlowski, and T Takeshita, and W H Boehncke, and H Takahashi, and L F Boyd, and R N Germain, and J A Berzofsky, and D H Margulies
November 1982, Molecular immunology,
S Kozlowski, and T Takeshita, and W H Boehncke, and H Takahashi, and L F Boyd, and R N Germain, and J A Berzofsky, and D H Margulies
April 1994, Nature,
S Kozlowski, and T Takeshita, and W H Boehncke, and H Takahashi, and L F Boyd, and R N Germain, and J A Berzofsky, and D H Margulies
September 2007, Journal of immunology (Baltimore, Md. : 1950),
S Kozlowski, and T Takeshita, and W H Boehncke, and H Takahashi, and L F Boyd, and R N Germain, and J A Berzofsky, and D H Margulies
January 1994, Scandinavian journal of immunology,
S Kozlowski, and T Takeshita, and W H Boehncke, and H Takahashi, and L F Boyd, and R N Germain, and J A Berzofsky, and D H Margulies
November 1996, Journal of immunology (Baltimore, Md. : 1950),
S Kozlowski, and T Takeshita, and W H Boehncke, and H Takahashi, and L F Boyd, and R N Germain, and J A Berzofsky, and D H Margulies
January 1984, Experimental and clinical immunogenetics,
S Kozlowski, and T Takeshita, and W H Boehncke, and H Takahashi, and L F Boyd, and R N Germain, and J A Berzofsky, and D H Margulies
January 2002, Biochemical and biophysical research communications,
S Kozlowski, and T Takeshita, and W H Boehncke, and H Takahashi, and L F Boyd, and R N Germain, and J A Berzofsky, and D H Margulies
January 1993, International journal of clinical & laboratory research,
S Kozlowski, and T Takeshita, and W H Boehncke, and H Takahashi, and L F Boyd, and R N Germain, and J A Berzofsky, and D H Margulies
December 1990, Science (New York, N.Y.),
Copied contents to your clipboard!